UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June 27~~August 2, 2023

CHINA HEALTH INDUSTRIES HOLDINGS, INC.
(Exact name of Registrant as specified in its Charter)

Delaware

000-51060

86-0827216

(State or other jurisdiction

of incorporation)

(Commission File No.)

(IRS Employer

Identification No.)

3199-1 Longxiang Road, Songbei District
Harbin City, Heilongjiang Province
People’s Republic of China, 150028
(Address of principal executive offices) (Zip Code)

86-451-88100688
(Registrant’s Telephone Number)

Not Applicable
(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Not Applicable		Not Applicable		Not Applicable

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2) ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

~~Item~~ITEM 14.01 ~~Entry~~CHANGES ~~into~~IN aREGISTRANT’S ~~Material~~CERTIFYING ~~Definitive Agreement~~ACCOUNTANT.

On ~~June~~August 272, 2023, (the ~~“Signing~~Board ~~Date”),~~of ~~Harbin~~Directors ~~Humankind Biology Technology Co., Limited (“Humankind”), a wholly owned subsidiary~~ of China Health Industries Holdings, Inc. ~~(“China Health”)~~, a corporation incorporated under the laws of the State of Delaware~~, entered~~ ~~into certain equity transfer agreements~~ (~~collectively,~~ the “~~Agreements~~Company”) ~~with Mr. Xin Sun and Mr. Kai Sun (collectively,~~ ~~the~~approved ~~“Sellers”). Pursuant to~~ the ~~Agreements,~~dismissal ~~the Sellers agreed to transfer to Humankind 99% and 1%~~ of ~~the~~Centurion ~~equity~~ZD ~~interests of~~CPA ~~Heilongjiang~~& ~~HempCan Pharmaceuticals~~ Co., ~~Ltd.~~ (“~~HempCan~~Centurion”), for a consideration of RMB292,050,000 (approximately $40,507,365) and RMB2,950,000 (approximately $409,165) respectively, totaling RMB295 million (approximately $40,916,530) (collectively, the “Purchase Prices”). The Purchase Prices shall be fully paid to Sellers within 15 business days after the Signing Date, and the Sellers shall complete certain registration procedures, such as ~~change of equity ownership and change of business registration within 15 business days after full Purchase Prices are received. If Humankind is late in paying~~ the ~~Purchase~~Company’s ~~Prices,~~independent aregistered ~~0.1% per day late~~public ~~penalty~~accounting ~~on the amount of Purchase Prices that is paid late shall be paid to the Sellers. Mr. Xin Sun is China Health’s Chairman~~firm, ~~sole~~ ~~director~~effective ~~and sole executive officer and Mr~~immediately. ~~Kai Sun is Mr. Xin Sun’s younger brother.~~

~~After~~The ~~the~~reports ~~completion~~ of ~~the~~Centurion ~~equity~~on ~~transfer,~~the ~~Humankind~~financial ~~will~~statements ~~have~~of the ~~shareholder’s~~Company ~~rights~~as of and ~~fulfill~~for the ~~shareholder’s~~fiscal ~~obligations.~~years ~~The~~ended ~~Sellers~~June ~~shall~~30, ~~assist Humankind~~2022 inand ~~having~~2021 ~~shareholder’s~~did ~~rights~~not ~~and~~contain ~~fulfilling~~any ~~shareholder’s~~adverse ~~obligations.~~opinion or ~~Humankind~~disclaimer ~~shall~~of beopinion ~~entitled~~and towas ~~the~~not ~~profit and~~qualified ~~assume~~or ~~risk~~modified ofas ~~loss~~to ofuncertainty, ~~HempCan~~audit scope or accounting principles.

~~Founded~~During inthe ~~May 22, 2019, HempCan,~~Company’s ~~with~~two amost ~~total~~recent offiscal 22years ~~employees~~and asthe ofsubsequent ~~the~~interim ~~date~~period ofthrough ~~this~~August ~~report~~2, ~~has~~2023, ~~been~~there ~~engaging~~were inno ~~Research~~disagreements &with ~~Development,~~Centurion ~~production~~on any ~~and~~matter ~~marketing~~ of ~~innovative~~accounting ~~drugs~~principles asor ~~well~~practices, asfinancial ~~medical~~statement ~~devices~~disclosure, ~~and~~or ~~functional~~auditing ~~food.~~scope ~~HempCan~~or ~~commits~~procedure, ~~itself~~which todisagreement(s), if ~~providing~~not anresolved ~~innovative treatment~~ to ~~patients by~~the ~~developing~~satisfaction ~~a treatment approach with combination~~ of ~~anticancer~~Centurion, ~~immune~~would ~~improvement~~have ~~and~~caused ~~pain~~it ~~relief.~~to Inmake ~~addition,~~reference ~~HempCan~~to ~~also~~the ~~cooperates with~~subject ~~universities~~matter ~~and~~of ~~individual~~the ~~advisors~~disagreement(s) in toconnection ~~develop~~with ~~new~~its ~~products and new technique~~report. ~~Currently,~~During ~~HempCan~~the ~~owns~~Company’s two ~~anticancer~~most ~~drugs~~recent fiscal years and ~~holds~~ the ~~business~~subsequent ~~permit~~interim toperiod ~~plant~~through ~~hemp~~August 2, ~~hemp~~2023, ~~seed~~there ~~growing,~~were ~~cannabidiol~~no ~~(CBD)~~reportable ~~extraction~~events ~~and~~of ~~deep~~the ~~processing~~type ~~for~~described ~~other~~in ~~hemp~~Item 304(a)(1)(v) of Regulation ~~products~~S-K.

~~SIGNATURES~~The Company provided Centurion with a copy of the foregoing disclosure and requested Centurion to furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made therein. A copy of such letter furnished by Centurion is filed as Exhibit 16.1 to this Form 8-K.

~~Pursuant~~On toAugust ~~the~~2, ~~requirements~~2023, of the ~~Securities~~Board of ~~Exchange~~Directors ~~Act~~ of ~~1934,~~ the ~~registrant~~Company ~~has~~approved ~~duly~~the ~~caused~~engagement ~~this~~of ~~report~~ARK toPro beCPA ~~signed~~& onCo ~~its~~(“ARK”) ~~behalf~~as byits ~~the~~new ~~undersigned~~independent ~~hereunto~~registered public ~~duly~~accounting ~~authorized~~firm.

	CHINA HEALTH INDUSTRIES HOLDINGS, INC.
Date: July 3, 2023	/s/ Xin Sun
	By:	Xin Sun
	Title:	Chief Executive Officer and Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

During the Company’s two most recent fiscal years and the subsequent interim period through August 2, 2023, neither the Company nor anyone on its behalf consulted with ARK regarding (i) the application of accounting principles to a specified transaction, either completed or proposed; the type of audit opinion that might be rendered on the Company's financial statements, and neither a written report nor oral advice was provided that ARK concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and its related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Exhibit No.		Description
16.1		Letter from Centurion ZD CPA & Co. dated August 4, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CHINA HEALTH INDUSTRIES HOLDINGS, INC.

Date: August 4, 2023	/s/ Xin Sun
	By:	Xin Sun
	Title:	Chief Executive Officer and Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

Filing Compare · China Health Industries Holdings, Inc.